To access this element change to forms mode OFF
Grant Award View - GA289008
Novel, targeted therapies for heart failure with preserved ejection...
GA ID:
GA289008
Agency:
Department of Health and Aged Care
Approval Date:
7-Dec-2022
Publish Date:
20-Mar-2023
Category:
Medical Research
Grant Term:
1-Feb-2023 to 31-Jan-2026
Value (AUD):
$1,098,168.29
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
Novel, targeted therapies for heart failure with preserved ejection fraction
Purpose:
Heart failure with preserved ejection fraction (HFpEF) is the predominant form of heart failure with no effective treatment currently available. Inflammation and oxidative stress are the key factors driving HFpEF pathologies. The enzyme, namely, ASK1, is the convergent point of HFpEF pathologies and a potential therapeutic target. ASK1 inhibitors to be developed in this study will provide new treatment improving the management and quality of life for HFpEF patients.
GO ID:
GO Title:
MRFF – Cardiovascular Health Mission – 2022 Cardiovascular Health Grant Opportunity
Internal Reference ID:
2022/MRF2024449
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Baker Heart and Diabetes Institute
Recipient ABN:
98 131 762 948
Grant Recipient Location
Suburb:
Melbourne
Town/City:
Melbourne
Postcode:
3004
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA